Nature Human Behaviour study finds SilverCloud® by Amwell® reduced prevalence of mental disorders over two years at scale
Rhea-AI Summary
Amwell (NYSE: AMWL) reported results from a large, NIMH-funded randomized trial of its SilverCloud digital behavioral health platform, published in Nature Human Behaviour. The study followed 6,205 at-risk college students over two years across 26 U.S. campuses.
Students offered SilverCloud showed 74.4% participation versus 30.2% with traditional behavioral health pathways and had 4.3% lower prevalence of any measured mental disorder at six weeks, 4.9% at six months, and 3.8% at two years. According to Amwell, this difference could correspond to about $1.18 million in avoided mental health–related costs within the study sample.
AI-generated analysis. Not financial advice.
Positive
- Large independent trial: 6,205 students across 26 U.S. colleges and universities
- Participation 74.4% with SilverCloud versus 30.2% with traditional behavioral health pathways
- Lower prevalence of any measured mental disorder: 4.3% at six weeks, 4.9% at six months, 3.8% at two years
- Estimated up to approximately $1.18 million in avoided mental health–related costs within the study sample
- Benefits reported across diverse student groups, including minoritized students and those with financial stress
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AMWL is down 2.7% while peers show mixed moves: HCAT +2.59%, MNDR +1.79%, FORA +0.46%, CCLD -1.4%, SOPH -0.22%. This points to stock-specific trading rather than a clear sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Investor conference | Neutral | -3.2% | Announcement of participation in virtual Needham technology and media conference. |
| May 05 | Quarterly earnings | Positive | +12.4% | Reported Q1 2026 results and hosted an earnings conference call. |
| Apr 20 | Earnings date set | Neutral | -4.5% | Scheduled Q1 2026 results release and related earnings call details. |
| Feb 24 | Investor conference | Neutral | +0.2% | Planned appearance at TD Cowen health care conference with a fireside chat. |
| Feb 18 | Inducement grant | Neutral | -1.7% | Grant of 61,559 RSUs to a new employee under inducement plan. |
Recent history shows mixed reactions: a strong gain on earnings, but several neutral items (conference appearances, routine grants) coincided with declines, suggesting sensitivity to broader factors beyond headline tone.
Over the last few months, AMWL news centered on earnings, investor conferences, and routine corporate actions. The Feb 18 inducement RSU grant and multiple conference participation announcements drew modest to negative moves, while Q1 2026 earnings on May 5 saw a strong +12.42% reaction. Today’s Nature Human Behaviour study adds clinical-scale validation for its digital behavioral health platform, contrasting with the more financial and corporate focus of prior news.
Market Pulse Summary
This announcement highlights large-scale, independently led evidence that Amwell’s SilverCloud program improved engagement and reduced mental disorder prevalence over up to two years, with up to $1.18 million in avoided costs within the study sample. In the context of recent earnings focused on cost discipline and visit volumes, the study adds external validation for the platform’s clinical and economic relevance. Investors may watch for future disclosures connecting such outcomes data to contracts, adoption metrics, and revenue trends.
Key Terms
randomized trial technical
AI-generated analysis. Not financial advice.
BOSTON, May 18, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today highlighted results from an independently led, National Institute of Mental Health-funded randomized trial published in Nature Human Behaviour examining SilverCloud® by Amwell®, the company’s digital behavioral health solution.
Conducted across 26 U.S. colleges and universities, the study included 6,205 students at clinical or high-risk levels for anxiety, depression, and/or eating disorders, making it one of the largest independent studies of its kind.
The study, led by renowned investigators from Washington University, Penn State University and University of California, Los Angeles, used a proactive care model designed to reach students before conditions worsened. Researchers screened nearly 40,000 students and offered support to those identified as being at elevated risk, rather than relying only on traditional pathways that require students to seek care on their own.
Principal Investigator Michelle G. Newman, PhD, Professor of Psychology and Psychiatry, Penn State University shares her insights on the study:
"Our goal was early detection of those at risk or meeting clinical levels for five mental health conditions, and to test whether digital mental health could move care upstream — reaching people earlier, before symptoms worsen, and doing so at population scale.”
Individuals offered SilverCloud were over twice as likely to engage:
74.4% participation with SilverCloud30.2% participation with traditional behavioral health solutions
Compared to screening and referral to in-person care, those who received digital behavioral healthcare had:
4.3% lower prevalence of having any mental disorder at six weeks4.9% lower prevalence at six months3.8% lower prevalence at two years
This positive impact was consistent across student populations, including minoritized students and those experiencing financial stress. The findings also point to the potential economic value of prevention and earlier intervention at scale.
When asked about the impact of the study, co-investigator Daniel Eisenberg, PhD, Health Economist, Professor of Health Policy and Management, UCLA said,
“The findings suggest meaningful potential economic value. Taking into account the
The findings add to the evidence supporting digital mental health programs as part of a broader care strategy for higher education institutions, health plans, and other organizations seeking to expand access to clinically rigorous support. By combining proactive outreach with a structured digital intervention, the study points to a model that may help address both participation and long-term outcomes in populations with significant unmet need.
About Amwell
Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access to more convenient, affordable and effective care. The Amwell Platform includes software and services that power many clinical programs from Amwell and our growing number of partners. Our platform allows patients to experience unified, personalized and simple access to diversified clinical programs across the care continuum. As more people seek care online and more clinical programs become available, we offer integrated, future-ready, consistent solutions. The Amwell Platform is proven, operating at a large scale, enabling care for millions of patients and their sponsors while delivering dependable outcomes. For almost two decades, Amwell has proudly served some of the largest and most sophisticated healthcare organizations in the U.S. and worldwide. For more information, visit business.amwell.com or LinkedIn.
Investors:
Asher Dewhurst
Media:
